Search
News
Emese Zsiros, MD, PhD, to Lead Gynecologic Oncology Program at Roswell Park
News
Landmark Study Led by Roswell Park Expert Shows Survival Benefit of Immunotherapy in Resistant Ovarian Cancer
News
Roswell Park Study: Chronic Opioid Use Reduced by Limiting Prescribed Opioids After Surgery
News
Roswell Park Team Identifies Factors That Boost Effectiveness of Immunotherapy in Recurrent Ovarian Cancer
… of Immunotherapy in Recurrent Ovarian Cancer Dr. Emese Zsiros leads work exploring interactions of tumor, … treatment options. The study’s senior author, Emese Zsiros, MD, PhD, FACOG , Chair of Gynecologic Oncology and … that does not respond to platinum-based treatments. Dr. Zsiros and her colleagues took the results a step further in …
News
Roswell Park Team Assesses Addition of Complement Inhibitor Drug to Immunotherapy for Ovarian Cancer
News
Roswell Park Researchers Uncover Clues to Immunotherapy Response in Patients with Recurrent Ovarian Cancer
Clinical Trial
A Phase I First-In-Human, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
… SIM0505 in Adult Participants with Advanced Solid Tumors I Zsiros, Emese This is an open-label, multicenter phase 1 …
Clinical Trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY FOR LNCB74, A B7-H4 TARGETED ANTIBODY DRUG CONJUGATE, AS MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
… MONOTHERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS I Zsiros, Emese This is an open-label, phase 1, dose escalation …
News
Roswell Park Community Comes Together to Celebrate Outstanding Physicians
Clinical Trial